Peer-reviewed veterinary case report
Safety of intravenous stem cell treatment in 40 dogs
By Cho, Hee-Seon et al.·Published in BMC veterinary research·2024·Department of Veterinary Clinical Science, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Intravenous injection of allogenic canine mesenchymal stem cells in 40 client-owned dogs: a safety assessment in veterinary clinical trials.
- Species:
- dog
Plain-English summary
Forty dogs received intravenous injections of stem cells derived from fat tissue to treat various health issues, and researchers monitored them for any side effects over six months. Fortunately, there were no significant adverse effects noted during physical exams, blood tests, or X-rays, and no new tumors developed in any of the dogs. This suggests that using these stem cells could be a safe treatment option for dogs with certain medical conditions.
People also search for: dog stem cell therapy safety · intravenous stem cells for dogs · dog treatment with mesenchymal stem cells
Abstract
BACKGROUND: The aim of this study was to evaluate the adverse effects of allogeneic mesenchymal stem cells (MSCs) transplanted via intravenous infusion in dogs and examine their safety. We performed a retrospective analysis of various clinical assessments, including physical examination, blood tests, and radiographs, and monitored the formation of neoplasms during a 6-month follow-up period in 40 client-owned dogs that received intravenous infusion of adipose tissue-derived MSCs (AT-MSCs) for the treatment of various underlying diseases between 2012 and 2018. RESULTS: No significant adverse effects of MSC therapy were detected by clinical assessment, blood tests, or radiographic examination in the 6-month follow-up period after the first MSC treatment. Additionally no new neoplasms were observed during this period. CONCLUSIONS: To our knowledge, this study is the first to evaluate the safety aspects (≥ 6 months) associated with intravenous allogeneic AT-MSC infusion. These results suggest that allogenic AT-MSC infusion could be a useful and relatively safe therapeutic approach in canines.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39174969/